The latest trading session saw Abbott (ABT) ending at $132.65, denoting a +1.4% adjustment from its last day's close. The stock exceeded the S&P 500, which registered a gain of 0.55% for the day.

Abbott (NYSE: ABT) today announced data demonstrating substantial, sustained improvements with its TriClip system.

Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes. Read why ABT stock is a Hold.

The Volt PFA system. [Image courtesy of Abbott] Abbott (NYSE: ABT) + announced it received CE mark approval in Europe for its ...

NORTHAMPTON, MA / ACCESS Newswire / February 21, 2025 / Abbott: Abbott medical device course at Prairie View A&M University introduces students to medical device careers. Abbott What do you think ...

BD, Medtronic and Abbott were among the top 10 device companies with the highest number of late reports to the FDA, the study ...

Abbott has announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) ...

The company is first rolling out the use of the Volt system among European Union doctors who have already gained experience ...

But for a Hanover, Minnesota, family, a prenatal checkup turned into quite a medical journey ... invasive: a device inserted through an incision in the leg, called the Abbott Amplatzer Device.

Abbott is joining the worldwide race to make pulsed field ablation the standard procedure for atrial fibrillation with an ...